Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany
CIMT 2011 was the ninth annual meeting organized by the Association for Cancer Immunotherapy (CIMT). More than 500 international participants met in Mainz, Germany, to discuss the latest topics in cancer immunotherapy. A total of 176 posters were presented by young scientists, and several of them were selected for short talk sessions. Three industry satellite symposia provided insights into new developments in state-of-the-art technologies to enhance cancer immunotherapy. The major topics of CIMT 2011 were trends in cellular therapies, therapeutic vaccination, improving immunity, immunoguiding, regulatory research and optimizing early clinical trials. This meeting report summarizes selected presentations to give an overview over the fields discussed during the meeting.
Immunotherapy: recent approvals and promising clinical trials shape the new field of immuno-oncology
Exactly 2 months prior to CIMT 2011, the FDA approved ipilimumab (anti-CTLA-4) as a new treatment for late-stage...
KeywordsIpilimumab Cancer Immunotherapy Cancer Vaccine Fred Hutchinson Cancer Research Immunogenic Cell Death
Conflict of interest
CMB is executive director of CIMT and co-organizer of CIMT 2011. All authors declare no conflict of interest.